Literature DB >> 8728022

Synergistic effects of thalidomide and poly (ADP-ribose) polymerase inhibition on type II collagen-induced arthritis in mice.

H Kröger1, R Miesel, A Dietrich, M Ohde, E Rajnavölgyi, H Ockenfels.   

Abstract

The present study investigates synergistic effects of the TNF-alpha inhibitor thalidomide and the poly(ADP-ribose) polymerase (PARP)-inhibitor nicotinic acid amide (NAA) in male DBA/1 hybird mice suffering from type II collagen-induced arthritis. Parameters including the arthritis index, chemiluminescence and anti-collagen antibody titers were used for the assessment of disease activity: The disease courses demonstrated clearly an inhibitory effect of thalidomide. NAA inhibited established collagen arthritis in a dose-dependent manner. The combined application of thalidomide and NAA caused a powerful synergistic inhibition of arthritis. Furthermore, thalidomide and NAA were tested ex vivo for their inhibition of the NADPH oxidase-dependent generation of reactive oxygen species by activated neutrophils and monocytes in unseparated human blood. Our data show that type II collagen-induced arthritis can be suppressed by the simultaneous inhibition of TNF-alpha, PARP, and NADPH oxidase.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8728022     DOI: 10.1007/BF01487406

Source DB:  PubMed          Journal:  Inflammation        ISSN: 0360-3997            Impact factor:   4.092


  36 in total

1.  Regulation by ADP-ribosylation.

Authors:  G de Murcia; M Jacobson; S Shall
Journal:  Trends Cell Biol       Date:  1995-02       Impact factor: 20.808

2.  Chronic bullous disease of childhood and ulcerative colitis.

Authors:  J Handley; M Shields; J Dodge; M Walsh; A Bingham
Journal:  Pediatr Dermatol       Date:  1993-09       Impact factor: 1.588

3.  Primed lymphocytes are boosted by type II collagen of their hosts after adoptive transfer.

Authors:  A Dietrich; N A Mitchison; E Rajnavölgyi; S C Schneider
Journal:  J Autoimmun       Date:  1994-10       Impact factor: 7.094

4.  Thalidomide: can it continue to be used?

Authors:  F Teixeira; M T Hojyo; R Arenas; M E Vega; R Cortes; A Ortiz; L Dominguez
Journal:  Lancet       Date:  1994-07-16       Impact factor: 79.321

Review 5.  Pharmacologic prophylaxis of acute graft-versus-host disease after allogeneic marrow transplantation.

Authors:  T L Schwinghammer; E J Bloom
Journal:  Clin Pharm       Date:  1993-10

Review 6.  Thalidomide--the need for a new clinical evaluation of an old drug.

Authors:  G Ehninger; K Eger; A Stuhler; U Schuler
Journal:  Bone Marrow Transplant       Date:  1993       Impact factor: 5.483

7.  Role of ADP-ribosylation in endothelial signal transduction and prostacyclin production.

Authors:  H Halldórsson; T Bödvarsdóttir; M Kjeld; G Thorgeirsson
Journal:  FEBS Lett       Date:  1992-12-21       Impact factor: 4.124

8.  Induction of arthritis in mice and rats by potassium peroxochromate and assessment of disease activity by whole blood chemiluminescence and 99mpertechnetate-imaging.

Authors:  R Miesel; H Kröger; M Kurpisz; U Weser
Journal:  Free Radic Res       Date:  1995-09

9.  Treatment of refractory rheumatoid arthritis--the thalidomide experience.

Authors:  O Gutiérrez-Rodríguez; P Starusta-Bacal; O Gutiérrez-Montes
Journal:  J Rheumatol       Date:  1989-02       Impact factor: 4.666

10.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis.

Authors:  J Keffer; L Probert; H Cazlaris; S Georgopoulos; E Kaslaris; D Kioussis; G Kollias
Journal:  EMBO J       Date:  1991-12       Impact factor: 11.598

View more
  7 in total

1.  Enhancing the inhibitory effect of nicotinamide upon collagen II induced arthritis in mice using N-acetylcysteine.

Authors:  H Kröger; A Hauschild; M Ohde; K Bache; W P Voigt; W Ehrlich
Journal:  Inflammation       Date:  1999-04       Impact factor: 4.092

2.  Enhancement of the effect of methotrexate on collagen II induced arthritis in mice by nicotinamide.

Authors:  H Kröger; A Hauschild; M Ohde; W Thefeld; D Krüger; K Bache; W Ehrlich
Journal:  Inflammation       Date:  1998-06       Impact factor: 4.092

3.  Poly(ADP-ribose) polymerase 1 at the crossroad of metabolic stress and inflammation in aging.

Authors:  Matthias Altmeyer; Michael O Hottiger
Journal:  Aging (Albany NY)       Date:  2009-05-20       Impact factor: 5.682

4.  The Val762Ala polymorphism in the poly(ADP-ribose) polymerase-1 gene is not associated with susceptibility in Turkish rheumatoid arthritis patients.

Authors:  Ilhan Onaran; Gülçin Tezcan; Levent Ozgönenel; Esra Cetin; Alper Tunga Ozdemir; Gönül Kanigür-Sultuybek
Journal:  Rheumatol Int       Date:  2008-11-22       Impact factor: 2.631

Review 5.  Diverse therapeutic efficacies and more diverse mechanisms of nicotinamide.

Authors:  Seon Beom Song; Jin Sung Park; Gu June Chung; In Hye Lee; Eun Seong Hwang
Journal:  Metabolomics       Date:  2019-10-05       Impact factor: 4.290

Review 6.  Mechanism of immunomodulatory drugs' action in the treatment of multiple myeloma.

Authors:  Xiubao Chang; Yuanxiao Zhu; Changxin Shi; A Keith Stewart
Journal:  Acta Biochim Biophys Sin (Shanghai)       Date:  2013-12-29       Impact factor: 3.848

Review 7.  The Role of Poly(ADP-ribose) Polymerase-1 in Rheumatoid Arthritis.

Authors:  Samuel García; Carmen Conde
Journal:  Mediators Inflamm       Date:  2015-03-03       Impact factor: 4.711

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.